Study to Evaluate the Efficacy and Safety of AstroStem-V in Treatment of COVID-19 Pneumonia
Status:
Not yet recruiting
Trial end date:
2023-04-01
Target enrollment:
Participant gender:
Summary
This study is an open-label, single-arm study to evaluate the safety and efficacy of
Astrostem-V, allogenic adipose tissue derived mesenchymal stem cells (AdMSC), in patients
with COVID-19 pneumonia. After each subject completes 12-Weeks visit (Visit 12) and the data
management team confirms all individual data have no issue, the individual database will be
locked and the blinding will be open for the statistical analysis.